Project Grant R56AR085145
- This federal Project Grant award, valued at $1,901,310.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project aims to investigate how skin inflammation drives the development of psoriatic arthritis, a condition that affects up to one-third of individuals with psoriasis. The project will use a novel mouse model to study the...
- This federal Project Grant award of $1,617,503 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting research to improve understanding and treatment of pain associated with psoriatic arthritis. The key products or services to be delivered through this award include: Improving and validating a mouse model for studying pain mechanisms in psoriatic arthritis....
- This federal Project Grant award of $664,933 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis. The research will utilize a novel animal model to define the early pathogenic pathways driven by IL-17A that contribute to joint and skin inflammation,...
- This federal Project Grant award of $390,913 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a mechanistic investigation into the role of the protein SERPINB3 in the pathogenesis of psoriasis. The research project, being conducted by Arizona State University, will explore the hypothesis that the misprocessing of SERPINB3 is the initiating factor in the...
- This federal Project Grant award, valued at $164,830.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research led by Dr. Alexis Ogdie at the University of Pennsylvania. The primary objectives are to: 1) quantify the impact and interrelationships of potentially modifiable risk factors, including obesity, depression, and anxiety, on treatment response...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define and treat genetic abnormalities in overlapping rashes of psoriasis and atopic dermatitis (termed "PSO-AD"). The $628,968 award to the University of California, San Francisco will leverage innovative biomarker techniques, including spatial transcriptomics and...
- The federal Project Grant award titled "Immune Cell Contributions to Inflammatory Arthritis" is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $735,460 award to Vanderbilt University Medical Center will support research to investigate the roles of B cells and inflammatory cytokines in the pathogenesis of psoriatic arthritis (PSA) using a mouse model...
- This $527,760 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research on the role of endogenous retroviruses in autoimmune diseases like rheumatoid arthritis (RA). The award to the University of California, San Francisco will support a study to identify the specific antigens and mechanisms by which self-reactive T cells evade tolerance and...
- This $3,406,145 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The award will support a 4-year research project investigating the role of the bone marrow's hematopoietic stem cell niche and its immune privilege in the pathogenesis of psoriatic arthritis. The research aims to...
- This federal Project Grant award of $528,558.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The goal of the research project is to study the immune system mechanisms underlying treatment resistance and paradoxical inflammatory side effects in patients with atopic dermatitis who receive the antibody therapy dupilumab. The research will...
This $300,000 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to the University of Rochester. The project aims to "Decipher the Endotypes and Signature of Non-Response in a Humanized Murine Model of PSA" for psoriatic arthritis, a chronic inflammatory disease. The research will (1) identify cellular and molecular signatures across psoriatic arthritis tissue domains, (2) define CD8+ T cell clonotypes to uncover candidate autoantigens, and (3) test whether the defensin protein hornerin is an autoantigen, using a humanized mouse model. The grant period runs from September 5, 2025 to August 31, 2026 and supports the development of biomarkers to enable personalized treatment strategies for this complex condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $300.0k | 9/1/25 |